Contact
searchSearch
HMP Global

August 2012 - FRMC

Physicians Surveyed about Strategies to Contain Costs
08/14/2013
Tori Socha
Strategies suggested to curb increasing healthcare costs in the United States often focus on physicians, calling for reductions in waste and increased conservative stewardship of resources. Noting the importance of physicians’ perspectives on...
Strategies suggested to curb increasing healthcare costs in the United States often focus on physicians, calling for reductions in waste and increased conservative stewardship of resources. Noting the importance of physicians’ perspectives on...
Strategies suggested to curb...
08/14/2013
First Report Managed Care
MEK Inhibition in BRAF-Mutated Melanoma
08/16/2012
Kevin L. Carter
Until recently, there was no systemic therapy shown to improve overall survival among patients with metastatic melanoma, and only modest improvements were observed with interferon as an adjuvant drug. Ipilimumab, a monoclonal antibody...
Until recently, there was no systemic therapy shown to improve overall survival among patients with metastatic melanoma, and only modest improvements were observed with interferon as an adjuvant drug. Ipilimumab, a monoclonal antibody...
Until recently, there was no...
08/16/2012
First Report Managed Care
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
08/16/2012
Kevin L. Carter
The 5-year survival rate for adrenocortical carcinoma, a rare cancer with a poor prognosis, is <15% among patients with metastatic disease. Mitotane is the only drug approved for the treatment of adrenocortical carcinoma and is used both...
The 5-year survival rate for adrenocortical carcinoma, a rare cancer with a poor prognosis, is <15% among patients with metastatic disease. Mitotane is the only drug approved for the treatment of adrenocortical carcinoma and is used both...
The 5-year survival rate for...
08/16/2012
First Report Managed Care
Rapid Whole-Genome Sequencing in a Neonatal MRSA Outbreak
08/16/2012
Kevin L. Carter
Although rapid whole-genome sequencing has been successfully used as a research tool with discriminatory power in outbreaks, it is also potentially useful for its possible clinical utility in a diagnostic setting. A compelling target is...
Although rapid whole-genome sequencing has been successfully used as a research tool with discriminatory power in outbreaks, it is also potentially useful for its possible clinical utility in a diagnostic setting. A compelling target is...
Although rapid whole-genome...
08/16/2012
First Report Managed Care
Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer
08/16/2012
Kevin L. Carter
The administration of radioiodine (131I) has traditionally been part of therapy to patients with thyroid cancer after thyroidectomy; however, it is unclear whether this administration provides any benefit after a complete surgical resection....
The administration of radioiodine (131I) has traditionally been part of therapy to patients with thyroid cancer after thyroidectomy; however, it is unclear whether this administration provides any benefit after a complete surgical resection....
The administration of...
08/16/2012
First Report Managed Care
Patterns of Antiamyloid-β Antibodies in Typical and Atypical Alzheimer Disease
08/16/2012
Kevin L. Carter
A major feature of Alzheimer disease (AD) is the deposition of brain amyloid-β (Aβ) peptide. IgG antibodies directed to Aβ naturally occur in the elderly, and their serum and cerebrospinal fluid levels may be significantly altered in the...
A major feature of Alzheimer disease (AD) is the deposition of brain amyloid-β (Aβ) peptide. IgG antibodies directed to Aβ naturally occur in the elderly, and their serum and cerebrospinal fluid levels may be significantly altered in the...
A major feature of Alzheimer...
08/16/2012
First Report Managed Care
Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer
08/16/2012
Kevin L. Carter
Thyroid cancer is the most common endocrine cancer, with >48,000 new cases occurring each year in the United States. Most cases are differentiated thyroid cancer, which is associated with a high 10-year survival rate of 90% to 95%. Many...
Thyroid cancer is the most common endocrine cancer, with >48,000 new cases occurring each year in the United States. Most cases are differentiated thyroid cancer, which is associated with a high 10-year survival rate of 90% to 95%. Many...
Thyroid cancer is the most...
08/16/2012
First Report Managed Care
Short Sleep Duration and Risk for Strokes
08/16/2012
Tim Casey
Boston—Researchers found an association between adults of normal weight sleeping <6 hours per night and an increased risk of stroke symptoms, according to an analysis of 5666 people who were part of a large study that has tracked patients...
Boston—Researchers found an association between adults of normal weight sleeping <6 hours per night and an increased risk of stroke symptoms, according to an analysis of 5666 people who were part of a large study that has tracked patients...
Boston—Researchers found an...
08/16/2012
First Report Managed Care
Zolpidem Tartrate Sublingual Tablets to Treat Insomnia
08/16/2012
Tim Casey
Boston—According to a post hoc analysis of a double-blind, placebo-controlled cross-over study, patients who took 1.75 mg and 3.5 mg of zolpidem tartrate sublingual tablets had a significantly shorter time to sleep compared with those who...
Boston—According to a post hoc analysis of a double-blind, placebo-controlled cross-over study, patients who took 1.75 mg and 3.5 mg of zolpidem tartrate sublingual tablets had a significantly shorter time to sleep compared with those who...
Boston—According to a post hoc...
08/16/2012
First Report Managed Care
Aggressive BP Treatment Has No Benefit in Cardiovascular Disease Risk
08/16/2012
Tim Casey
Philadelphia—A subanalysis of a major randomized blood pressure trial found that patients who are centrally obese and have type 2 diabetes do not benefit in terms of cardiovascular disease risk when they are treated aggressively to lower...
Philadelphia—A subanalysis of a major randomized blood pressure trial found that patients who are centrally obese and have type 2 diabetes do not benefit in terms of cardiovascular disease risk when they are treated aggressively to lower...
Philadelphia—A subanalysis of a...
08/16/2012
First Report Managed Care

Behind the Bill

Behind the Bill
SCOTUS Takes on the Nondelegation Doctrine: Surprising Reactions and What They Mean for Agency Power
04/02/2025
Katie Hayes, MJ
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard...
04/02/2025
First Report Managed Care
Behind the Bill
Dr Oz’s Prescription for Making Medicaid “Viable at Every Level”
03/26/2025
Katie Hayes, MJ
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the...
03/26/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question Continues: Dr Oz's Confirmation and the Future of Medicaid
03/19/2025
Katie Hayes, MJ
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880...
03/19/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question: Can Congress Cut Spending Without Touching Medicaid?
03/12/2025
Katie Hayes, MJ
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from...
03/12/2025
First Report Managed Care
Behind the Bill
RFK Jr’s Public Comment Ban: The Silent Shift in Health Care Rulemaking
03/05/2025
Katie Hayes, MJ
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative...
03/05/2025
First Report Managed Care
Behind the Bill
Prevention Over Pills? The First 2 Weeks of Health Care’s New Direction
02/26/2025
Katie Hayes, MJ
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from...
02/26/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 2)
02/19/2025
Katie Hayes, MJ
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the...
02/19/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 1)
02/12/2025
Katie Hayes, MJ
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust...
02/12/2025
First Report Managed Care
Behind the Bill
No, President Trump Did Not Actually Sign an Executive Order That Would Increase Drug Costs for Beneficiaries
02/05/2025
Katie Hayes, MJ
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President...
02/05/2025
First Report Managed Care
Behind the Bill
Robert F. Kennedy Jr’s Confirmation and the Unexpected Turn in the Drug Pricing Debate
01/29/2025
Katie Hayes, MJ
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug...
01/29/2025
First Report Managed Care

Subscribe and Stay Ahead With Daily Industry Insights

First Report Managed Care Newsletter

Trending Articles

News
Improving Health Outcomes Through Early COPD and Asthma Intervention
10/04/2024
Hannah Musick
Research published in the New England Journal of Medicine shows that early diagnosis and treatment of undiagnosed COPD or asthma can reduce health care utilization for respiratory illness and improve overall health outcomes.
Research published in the New England Journal of Medicine shows that early diagnosis and treatment of undiagnosed COPD or asthma can reduce health care utilization for respiratory illness and improve overall health outcomes.
Research published in the New...
10/04/2024
First Report Managed Care
News
Advances in Factor IX Therapy Offer New Hope for Hemophilia B Treatment
10/23/2024
Lisa Kuhns, PhD, MD
New factor IX therapies promise improved treatment for hemophilia B.
New factor IX therapies promise improved treatment for hemophilia B.
New factor IX therapies promise...
10/23/2024
First Report Managed Care
News
JAK Inhibitor Improves Symptoms in Patients With Psoriatic Arthritis and Axial Involvement
04/21/2023
Jolynn Tumolo
In two phase 3 studies comparing upadacitinib to placebo and adalimumab, upadacitinib improved symptoms in patients with psoriatic arthritis and axial involvement.
In two phase 3 studies comparing upadacitinib to placebo and adalimumab, upadacitinib improved symptoms in patients with psoriatic arthritis and axial involvement.
In two phase 3 studies comparing...
04/21/2023
First Report Managed Care
News
Risk of Psychiatric Comorbidity Higher in Patients With Ankylosing Spondylitis
05/19/2023
Jolynn Tumolo
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a...
05/19/2023
First Report Managed Care
Conference Coverage
Significant Number of Solid Tumor Drug Approvals Added Complexity to Existing Regimens
06/08/2023
Maria Asimopoulos
A significant portion of drug approvals for nonhematologic solid cancers in the last 12 years were for indications which added to existing regimens, which could increase costs and exposure to side effects, researchers said.
A significant portion of drug approvals for nonhematologic solid cancers in the last 12 years were for indications which added to existing regimens, which could increase costs and exposure to side effects, researchers said.
A significant portion of drug...
06/08/2023
First Report Managed Care

August 2012 Volume 9 Issue 8

View Issue Archive
Editorial Correspondence

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use